192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4041-4046

  Öztürk, Oǧuz ^a   Kaǧnici, Ömer F ^a   Öztürk, Tülin ^a   Durak, Haydar ^a   Tüzüner, Bora M ^a   Kisakesen, Halil I ^a   Çakalir, Canser ^a   Isbir, Turgay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Arylamine metabolism; Arylesterase; Bladder cancer; Detoxification; Genetic polymorphism; PON1

Indexed keywords

ACETIC ACID; AROMATIC AMINE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; FREE RADICAL; PARAOXON; SCAVENGER; SULFATE; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; BIOTRANSFORMATION; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INVASION; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; CYSTECTOMY; DNA POLYMORPHISM; ENZYME ACTIVITY; ESTERIFICATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLDIALKYLPHOSPHATASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 71949107672     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Natioanal Cancer Institute. What You Need to Know About Bladder Cancer. http://www.cancer.gov/cancertopics/wyntk/bladder (Accessed May 8, 2009).
2. Cohen SM, Shirai T and Steineck G: Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 205: 105-115, 2000. (Pubitemid 32056470)
3. Mackness MI, Arrol S and Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286: 152-154, 1991.
4. Costa LG, Cole TB, Jarvik GP and Furlong CE: Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54: 371-392, 2003.
5. Biggadike K, Angell MR, Burgess CM, Farrell RM, Hancock AP, Harker AJ, Irving WR, Ioannou C, Procopiou PA, Shaw RE, Solanke YE, Singh OMP, Snowden MA, Stubbs RJ, Walton S and Weston HE: Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism. J Med Chem 43: 19-21, 2000. (Pubitemid 30055759)
6. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A and Eskenazi B: PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmocogenet Genomics 16: 183-190, 2006. (Pubitemid 43312580)
7. Ue CH, Lee KY, Choe KH, Hong YC, Kim YD, Kang JW and Kim H: Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Public Health 35: 345-350, 2005.
8. Bedia Aǧaçhan, İlhan Yaylim, H. Arzu Ergen, Soykan Arikan, Seden Küçücük, Hülya Yilmaz, S. Ümit Zeybek, Savaş Bayrak, Nilüfer Bozkurt, Uzay Görmüş and Turgay İsbir: Is paraoxonase 1 192 BB genotype risk factor for breast cancer? Adv Mol Med 2(1): 37-40, 2006.
9. Stevens VL, Rodriguez C, Talbot JT, Pavluck AL, Thun MJ and Calle EE: Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate 68: 1336-1340, 2008.
10. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY and Goodman MT: Genetic polymorphisms in the paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 17: 2070-2077, 2008.
11. Hashim Z and Zarina S: Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Clin Biochem 40: 705-709, 2007. (Pubitemid 46829081)
12. Eble NJ, Sauter G, Epstein JI and Sesterhann IA: Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours. Lyon, IARC Pres, pp. 89-154, 2004.
13. Wright DK and Manos MM: Sample preparation from paraffin-embedded tissues. In: PCR Protocols, A Guide to Methods and Applications. Inis MA, Gelfand DH, Sninsky JJ and White TJ, (eds.). UK Academic Press, pp. 153-158, 1990.
14. Miller SA, Dykes DD and Polesky HS: Simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215, 1988.
15. Adkins S, Gan KN, Mody M and La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52: 598-608, 1993. (Pubitemid 23311330)
16. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287, 1998. (Pubitemid 28335041)
17. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE and Bryan GT: N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology: Preliminary results in Sweden and Denmark. Int J Epidemiol 36(1): 11-18, 2007. (Pubitemid 47064254)
18. Gichner T, Veleminský J, Wagner ED and Plewa MJ: Mutagenic synergy between paraoxon and plant-activated m-phenylenediamine or 2- acetoxyacetylaminofluorene. Environ Mol Mutagen 27: 59-66, 1996. (Pubitemid 26091781)
19. Miller EC: Some current perspectives on chemical carcinogenesis in humans and experimental animals. Cancer Res 38: 1479-1496, 1978. (Pubitemid 8346654)
20. Young JF and Kadlubar FF: A pharmacokinetic model to predict exposure of the bladder epithelium to urinary N-hydroxyarylamine carcinogens as a function of urine pH, voiding interval, and resorption. Drug Metab Dispos 10(6): 641-644, 1982.
21. Ruddon RW: Cancer Biology: New York: Oxford University Press, pp. 22-23, 2007.
22. Khersonsky O and Tawfik DS: Structure reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44: 6371-6382, 2005. (Pubitemid 40570731)
23. Jung I and Messing E: Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 7: 325-334, 2000. (Pubitemid 30602198)